Drug discovery

Takara Bio offers hiPSC-derived cells and other stem cell and cell biology research products that can support your efforts to study SARS-CoV-2 infection, identify potential targets for drug discovery, evaluate the metabolism and safety of candidate drugs, and develop therapeutic approaches to treat COVID-19.

With our expertise in hiPSC culture and differentiation, we are able to provide functional, mature hiPSC-based models for studying viral transmission and infection in the heart, liver, pancreas, and intestinal epithelium. Our kits provide a renewable source of hiPSC-derived cells and address several limitations of the current gold-standard models, such as rapid loss of functionality, limited availability, interdonor variability of primary cells, and inability of immortalized cell lines to accurately reflect in vivo cell function. Our relevant, reliable cell culture systems, along with our Cellartis Power Primary HEP Medium for long-term culture of primary hepatocytes, are also ideal for evaluating the metabolism and toxicity of drug candidates.

For therapeutic research applications, we provide a mesenchymal stem cell culture medium that promotes efficient maintenance and expansion of mesenchymal stem cells from bone marrow, adipose tissue, or umbilical cord. Also, we provide an unparalleled extracellular vesicle isolation kit for studying the potential involvement of these vesicles in infection and for the development of potential therapeutic strategies.